Tocilizumab treatment with reducing and stopping methotrexate in patients with rheumatoid arthritis in stable low disease activity-state
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000021247
- Lead Sponsor
- agoya University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 53
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients receiving TCZ and/or MTX for any disease other than RA 2) Patients judged as inadequate at the discretion of physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients maintaining CDAI<=10 at 36 weeks (24weeks after stopping MTX)
- Secondary Outcome Measures
Name Time Method 1) Proportion of patients maintaining CDAI<=10 at 12 weeks (after reducing MTX) and 64 weeks (52weeks after stopping MTX) 2) Disease activity, serum concentration of TNF-alpha and IL-6, FSSG score, and EQ-5Dat each visit 3) Proportion of patients regaining CDAI<=10 4) Predictors of maintaining CDAI<=10 5) Adverse events